. Author manuscript; available in PMC: 2015 Feb 5.

Published in final edited form as: Clin Exp Pharmacol Physiol. 2009 Oct 16;37(2):e70–e77. doi: 10.1111/j.1440-1681.2009.05315.x

Table 1.

Systolic blood pressure, heart rate, heart weight to bodyweight ratio, cardiac collagen content, cGMP, angiotensin II, Thiobarbituric acid-reactive substances and fibrosis in Npr1^+/+ and Npr1^−/− mice treated with and without antihypertensive drugs

	Untreated		Hydralazine		Captopril
	Npr1⁺^/⁺	Npr1^−/−	Npr1⁺^/⁺	Npr1^−/−	Npr1⁺^/⁺	Npr^−/−
SBP (mmHg)	100 ± 4	130 ± 8***	97 ± 3	110 ± 6**^††	98 ± 4	106 ± 5**^††
HW/BW ratio	4.6 ± 0.3	7.5 ± 0.5*	4.7 ± 0.4	7.1 ± 0.7*	4.4 ± 0.2	5.3 ± 0.7*^†
cGMP (pmol/mg protein)	26 ± 5	5 ± 1***	25 ± 3	6 ± 1**	28 ± 6	10 ± 2^†
AngII (pmol/mg protein)	15 ± 2	32 ± 2***	14 ± 1	28 ± 3**	12 ± 1	17 ± 2^††
TBARS (nmol MDA/mg protein)	25 ± 3	38 ± 3***	23 ± 2	32 ± 2*	22 ± 2	23 ± 2^††
W/L ratio	0.10 ± 0.02	0.25 ± 0.07***	0.10 ± 0.03	0.2 ± 0.5**	0.1 ± 0.3	0.13 ± 0.03^††
MCA (μm²)	415 ± 22	915 ± 73***	413 ± 18	825 ± 34**	409 ± 16	562 ± 82*^††
Collagen (mg/g tissue)	1.4 ± 0.1	3.5 ± 0.7***	1.3 ± 0.3	2.4 ± 0.2**	1.2 ± 0.3	1.6 ± 0.4**^††
Fibrosis (%)	0.8 ± 0.3	25 ± 3***	0.9 ± 0.3	24 ± 2**	1.0 ± 0.2	7.6 ± 0.9**^††